tranexamic acid has been researched along with Angiohemophilia in 42 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 9.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 7.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 7.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 7.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 5.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| " Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies." | 5.41 | Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 5.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| " The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders." | 4.98 | Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018) |
| "8%) had menorrhagia, for which combined oral contraceptives, tranexamic acid and desmopressin were the most common first-line therapies for menorrhagia, whereas VWF was third-line therapy reported in 13 women (1." | 4.93 | Von Willebrand factor for menorrhagia: a survey and literature review. ( Brambilla, DJ; James, AH; Kessler, CM; Konkle, BA; Kouides, PA; Machin, N; Malec, LM; Neff, AT; Philipp, CS; Ragni, MV, 2016) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 3.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 3.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| "Four cases of menorrhagia in von Willebrand disease were successfully treated with tranexamic acid given in a single daily dose of 4 g for the first 3-5 days of the menstrual cycle." | 3.70 | Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. ( Hull, DR; Mayne, EE; Ong, YL, 1998) |
| "The most common form of BDs is von Willebrand Disease, reflecting 13% of adolescents with AUB." | 2.58 | Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. ( Deligeoroglou, E; Karountzos, V, 2018) |
| "In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women." | 2.43 | Women and von Willebrand disease: controversies in diagnosis and management. ( Chi, C; Kadir, RA, 2006) |
| "Tranexamic acid was usually added for mucosal surgery." | 2.41 | Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. ( Griffioen, A; Harrington, C; Lee, CA; Nitu-Whalley, IC, 2001) |
| "Peri-procedural management of von Willebrand disease (VWD) utilizes von Willebrand factor (VWF) concentrates or desmopressin (DDAVP) to increase VWF levels." | 1.91 | Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. ( Chandrakumaran, P; Hews-Girard, J; Poon, MC, 2023) |
| "Our review of the literature and the results of the survey showed considerable heterogeneity in treatment regimens, and a lack of consistency in reporting of the variables that determine factor concentrate dosing and monitoring." | 1.43 | Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. ( Altisent, C; Dolan, G; Katsarou, O; López Fernández, MF; Windyga, J; Zülfikar, B, 2016) |
| "We have analyzed the databases for von Willebrand disease (VWD) from the hemophilia center for adult patients with bleeding disorders in South Australia." | 1.37 | Diagnosis and management of adult patients with von Willebrand disease in South Australia. ( Duncan, EM; Lloyd, JV; Mangos, HM; McRae, SJ; Rodgers, SE, 2011) |
| "Hemophilia A and B and von Willebrand disease (VWD) belong to the most frequent congenital coagulation disorders and are a significant problem in patients who require periodontal therapy or tooth extraction." | 1.36 | Comprehensive treatment of periodontitis in patients with von Willebrand disease. ( Alesci, S; Eickholz, P; Miesbach, W; Nickles, K; Wohlfeil, M, 2010) |
| " Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia." | 1.31 | High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. ( Mohri, H, 2002) |
| "A 42-year-old female with von Willebrand's disease was managed with desmopressin and tranexamic acid to aid haemostasis following a vaginal hysterectomy." | 1.31 | Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. ( Bertholini, DM; Butler, CS, 2000) |
| "A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel." | 1.31 | Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.14) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 11 (26.19) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brignardello-Petersen, R | 2 |
| El Alayli, A | 2 |
| Husainat, N | 2 |
| Kalot, M | 1 |
| Shahid, S | 2 |
| Aljabirii, Y | 2 |
| Britt, A | 2 |
| Alturkmani, H | 2 |
| El-Khechen, H | 2 |
| Motaghi, S | 2 |
| Roller, J | 2 |
| Dimassi, A | 1 |
| Abughanimeh, O | 1 |
| Madoukh, B | 1 |
| Arapshian, A | 1 |
| Grow, JM | 1 |
| Kouides, P | 3 |
| Laffan, M | 1 |
| Leebeek, FWG | 1 |
| O'Brien, SH | 1 |
| Tosetto, A | 2 |
| James, PD | 2 |
| Connell, NT | 2 |
| Flood, V | 1 |
| Mustafa, RA | 2 |
| Kalot, MA | 1 |
| Abdul-Kadir, R | 1 |
| Couper, S | 1 |
| Lavin, M | 3 |
| Ozelo, MC | 1 |
| Weyand, A | 1 |
| Flood, VH | 1 |
| Chandrakumaran, P | 1 |
| Hews-Girard, J | 1 |
| Poon, MC | 1 |
| Ragni, MV | 2 |
| Rothenberger, SD | 1 |
| Feldman, R | 1 |
| Nance, D | 1 |
| Leavitt, AD | 1 |
| Malec, L | 1 |
| Kulkarni, R | 1 |
| Sidonio, R | 1 |
| Kraut, E | 1 |
| Lasky, J | 1 |
| Pruthi, R | 1 |
| Angelini, D | 1 |
| Philipp, C | 1 |
| Hwang, N | 1 |
| Wheeler, AP | 1 |
| Seaman, C | 1 |
| Machin, N | 2 |
| Xavier, F | 1 |
| Meyer, M | 1 |
| Bellissimo, D | 1 |
| Humphreys, G | 1 |
| Smith, KJ | 1 |
| Merricks, EP | 1 |
| Nichols, TC | 1 |
| Ivanco, D | 1 |
| Vehec, D | 1 |
| Koerbel, G | 1 |
| Althouse, AD | 1 |
| Eising, HP | 1 |
| Punt, MC | 1 |
| Leemans, JC | 1 |
| Bongers, MY | 1 |
| Lasry, A | 1 |
| Gil, Y | 1 |
| Balayla, J | 1 |
| Scott, M | 1 |
| Hay, CRM | 1 |
| Elkhalifa, S | 1 |
| Tower, C | 1 |
| Cocker, M | 1 |
| Thachil, J | 1 |
| Deligeoroglou, E | 1 |
| Karountzos, V | 1 |
| Lewandowski, B | 1 |
| Wojnar, J | 1 |
| Brodowski, R | 1 |
| Mucha, M | 1 |
| Czenczek-Lewandowska, E | 1 |
| Brzęcka, D | 1 |
| Bannow, BS | 1 |
| Konkle, BA | 2 |
| Tiede, A | 2 |
| van Galen, KP | 1 |
| Engelen, ET | 1 |
| Mauser-Bunschoten, EP | 1 |
| van Es, RJ | 1 |
| Schutgens, RE | 1 |
| Malec, LM | 1 |
| James, AH | 1 |
| Kessler, CM | 1 |
| Kouides, PA | 1 |
| Neff, AT | 1 |
| Philipp, CS | 1 |
| Brambilla, DJ | 1 |
| Appelmann, I | 1 |
| Kreher, S | 1 |
| Parmentier, S | 1 |
| Wolf, HH | 1 |
| Bisping, G | 1 |
| Kirschner, M | 1 |
| Bergmann, F | 1 |
| Schilling, K | 1 |
| Brümmendorf, TH | 1 |
| Petrides, PE | 1 |
| Matzdorff, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Koschmieder, S | 1 |
| Windyga, J | 1 |
| Dolan, G | 1 |
| Altisent, C | 1 |
| Katsarou, O | 1 |
| López Fernández, MF | 1 |
| Zülfikar, B | 1 |
| Eghbali, A | 1 |
| Melikof, L | 1 |
| Taherahmadi, H | 1 |
| Bagheri, B | 1 |
| Sánchez-Luceros, A | 1 |
| Woods, AI | 1 |
| Bermejo, E | 1 |
| Shukla, S | 1 |
| Acharya, S | 1 |
| Rydz, N | 1 |
| Othman, M | 1 |
| O'Donnell, JS | 1 |
| Nickles, K | 1 |
| Wohlfeil, M | 1 |
| Alesci, S | 1 |
| Miesbach, W | 1 |
| Eickholz, P | 1 |
| Mikhail, S | 1 |
| Rodgers, SE | 1 |
| Lloyd, JV | 1 |
| Mangos, HM | 1 |
| Duncan, EM | 1 |
| McRae, SJ | 1 |
| Nair, SC | 1 |
| Viswabandya, A | 1 |
| Srivastava, A | 2 |
| Jiménez-Yuste, V | 1 |
| Prim, MP | 1 |
| De Diego, JI | 1 |
| Villar, A | 1 |
| Quintana, M | 1 |
| Rabanal, I | 1 |
| Sastre, N | 1 |
| Hernández-Navarro, F | 1 |
| Mohri, H | 1 |
| Mannucci, PM | 2 |
| Morimoto, Y | 1 |
| Yoshioka, A | 1 |
| Sugimoto, M | 1 |
| Imai, Y | 1 |
| Kirita, T | 1 |
| Kadir, RA | 1 |
| Chi, C | 1 |
| Castaman, G | 1 |
| Rodeghiero, F | 1 |
| Cappelletti, A | 1 |
| Baudo, F | 1 |
| Eikenboom, JC | 2 |
| Federici, AB | 2 |
| Lethagen, S | 1 |
| Linari, S | 1 |
| Lusher, J | 1 |
| Nishino, M | 1 |
| Petrini, P | 1 |
| Ungerstedt, JS | 1 |
| Jackson, N | 1 |
| Hashim, ZA | 1 |
| Zainal, NA | 1 |
| Jamaluddin, N | 1 |
| Prinsley, P | 1 |
| Wood, M | 1 |
| Lee, CA | 2 |
| Ong, YL | 1 |
| Hull, DR | 1 |
| Mayne, EE | 1 |
| Onundarson, PT | 1 |
| Baerlocher, GM | 1 |
| Leoncini-Franscini, L | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Sacco, R | 1 |
| Stabile, F | 1 |
| Carpenedo, M | 1 |
| Zingaro, E | 1 |
| Bertholini, DM | 1 |
| Butler, CS | 1 |
| Nitu-Whalley, IC | 1 |
| Griffioen, A | 1 |
| Harrington, C | 1 |
| Stubbs, M | 1 |
| Lloyd, J | 1 |
| Meijer, K | 1 |
| Peters, FT | 1 |
| van der Meer, J | 1 |
| Nilsson, IM | 1 |
| Mikaelsson, M | 1 |
| Vilhardt, H | 1 |
| Walter, H | 1 |
| van der Meer, FJ | 1 |
| Briët, E | 1 |
| Pignanelli, M | 1 |
| Rota, L | 1 |
| Pignanelli, C | 1 |
| Vinckier, F | 1 |
| Vermylen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study[NCT02606045] | Phase 3 | 60 participants (Anticipated) | Interventional | 2019-02-07 | Active, not recruiting | ||
| National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042] | 1,100 participants (Anticipated) | Observational | 2007-07-31 | Completed | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
12 reviews available for tranexamic acid and Angiohemophilia
| Article | Year |
|---|---|
Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
Topics: Factor VIII; Hemostasis; Humans; Tranexamic Acid; von Willebrand Diseases; von Willebrand Factor | 2022 |
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas | 2023 |
Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.
Topics: Adolescent; Antifibrinolytic Agents; Contraceptives, Oral, Combined; Female; Humans; Menorrhagia; Me | 2018 |
Inherited Bleeding Disorders in the Obstetric Patient.
Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia | 2018 |
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia | 2015 |
Von Willebrand factor for menorrhagia: a survey and literature review.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Databases, Factual; Deamino Arginine Vasopressin; Fem | 2016 |
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |
New treatment approaches to von Willebrand disease.
Topics: Deamino Arginine Vasopressin; Hemorrhage; Humans; Tranexamic Acid; von Willebrand Diseases; von Will | 2016 |
Diagnosis and management of von Willebrand disease: a developing country perspective.
Topics: Clinical Laboratory Techniques; Coagulants; Deamino Arginine Vasopressin; Developing Countries; Fact | 2011 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Treatment of von Willebrand's Disease.
Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo | 2004 |
Women and von Willebrand disease: controversies in diagnosis and management.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Contraceptives, Oral, Synthetic; Deamino Arginine Vasopr | 2006 |
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Topics: Anesthesia, Obstetrical; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Deamino Ar | 2001 |
2 trials available for tranexamic acid and Angiohemophilia
| Article | Year |
|---|---|
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa | 2023 |
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine Vasopressin; D | 2000 |
28 other studies available for tranexamic acid and Angiohemophilia
| Article | Year |
|---|---|
Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
Topics: Female; Humans; Menorrhagia; Postpartum Hemorrhage; Pregnancy; Systematic Reviews as Topic; Tranexam | 2022 |
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Topics: Adolescent; Adult; Deamino Arginine Vasopressin; Factor VIII; Hemorrhage; Humans; Retrospective Stud | 2023 |
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
Topics: Adult; Cysts; Female; Hemorrhage; Humans; Ovulation; Pain; Pelvic Pain; Tranexamic Acid; Treatment O | 2020 |
Management of pregnancy in type 3 von Willebrand disease with alloantibodies.
Topics: Adult; Disease Management; Factor VIIa; Female; Humans; Isoantibodies; Platelet Transfusion; Pregnan | 2018 |
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop | 2018 |
Diagnosis and treatment of acquired von Willebrand syndrome.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine V | 2012 |
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Coagulants; Databases, Factual; Dose-Response Rel | 2016 |
Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
Topics: Antifibrinolytic Agents; Child, Preschool; Controlled Before-After Studies; Double-Blind Method; Fem | 2016 |
PT-VWD posing diagnostic and therapeutic challenges - small case series.
Topics: Adolescent; Child, Preschool; Deamino Arginine Vasopressin; Drug Therapy, Combination; Factor VIIa; | 2017 |
Comprehensive treatment of periodontitis in patients with von Willebrand disease.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Anti-Bacterial Agents; Chron | 2010 |
von Willebrand disease in the pediatric and adolescent population.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Contusions; Deamino Arginine Vasopres | 2010 |
Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Databases, Factual; Deamino Arginine Vasopr | 2011 |
Otolaryngologic surgery in children with von Willebrand disease.
Topics: Adenoidectomy; Adolescent; Antifibrinolytic Agents; Child; Child, Preschool; Deamino Arginine Vasopr | 2002 |
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2002 |
Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Chronically Ill; Factor VIII | 2005 |
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Deamino Arginine Vasopressin | 2006 |
Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies.
Topics: Adult; Antibodies, Antinuclear; Factor VIII; Female; Gingival Hemorrhage; Humans; Lupus Erythematosu | 1995 |
Adenotonsillectomy in patients with inherited bleeding disorders.
Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F | 1993 |
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.
Topics: Administration, Oral; Adolescent; Adult; Antifibrinolytic Agents; Drug Administration Schedule; Fema | 1998 |
Treatment of menorrhagia in von Willebrand's disease.
Topics: Adult; Antifibrinolytic Agents; Female; Humans; Menorrhagia; Tranexamic Acid; von Willebrand Disease | 1999 |
[Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease].
Topics: Autoantibodies; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Recurrence; Tranexamic Aci | 1999 |
Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease.
Topics: Acute Disease; Adult; Deamino Arginine Vasopressin; Female; Hemostatics; Humans; Hyponatremia; Hyste | 2000 |
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin; | 2001 |
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen | 2001 |
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas | 1979 |
Acquired von Willebrand's disease due to excessive fibrinolysis.
Topics: Blood Coagulation Disorders; Fibrinolysis; Hemorrhagic Disorders; Humans; Male; Middle Aged; Tranexa | 1992 |
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo | 1988 |
Dental extractions in hemophilia: reflections on 10 years' experience.
Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII; | 1985 |